Symptom burden at the end-of-life for neuroendocrine tumors: an analysis of 2,579 prospectively collected patient-reported outcomes

Rick Greene, MD and Julie Hallet, MD discuss the moderate-to-severe symptoms observed to steeply increase as death nears for patients with neuroendocrine tumors (NETs), which highlight an opportunity for improved management. Dr. Hallet is author of, “Symptom Burden at the End of Life for Neuroendocrine Tumors: An Analysis of 2579 Prospectively Collected Patient-Reported Outcomes.” Dr. Hallet is Assistant Professor, Surgical Oncology, University of Toronto and Sunnybrook Health Sciences Centre, Toronto, Canada.